Work

Disarming oxidized lipids: AAV-delivered antibody neutralization as an emerging strategy against ALS

Year: 2026

Type: article

Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive and devastating neurodegenerative disease affecting motor neurons (MNs) and the neuromuscular axis. Despite decades of research on its molecular trigger and pathological mechanisms, and the search for effective disease-modifying therapies, both questions remain largely unknown. A common feature of ALS, present in 97% of cases, is the mislocalization, aggregation, and functional disruption of TAR DNA-binding protein 43 (TDP-43),1 yet the upstream trigger of this proteinopathy is poorly understood.

Source: Molecular Therapy Advances

DOI: 10.1016/j.omta.2026.201879

Authors: Sergi Verdés, Assumpció Bosch

Institutions: Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Instituto de Salud Carlos III, Biomedical Research Networking Center on Neurodegenerative Diseases

Language: English

Topic: Amyotrophic Lateral Sclerosis Research

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W7225411104

FWCI:

Cites: 10

Cited by:

Related to: 10